Corcept Therapeutics Inc revenue
Corcept Therapeutics Inc's revenue was $761m in fiscal 2025, up 12.8% on the year before. Since fiscal 2009 ($29,000) it has grown at a compound 176.6% a year. Over the last twelve months it was $831m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 81 | 159 | 251 | 306 | 354 | 366 | 402 | 482 | 675 | 761 | 831 |
| Growth on the year before | — | +>999% | +95.8% | +57.8% | +22.0% | +15.5% | +3.4% | +9.8% | +20.0% | +39.9% | +12.8% | — |
| Gross profit | — | 79 | 156 | 246 | 301 | 348 | 361 | 396 | 476 | 664 | 748 | 817 |
| Gross margin | — | 97.5% | 97.8% | 97.9% | 98.2% | 98.4% | 98.6% | 98.7% | 98.7% | 98.4% | 98.3% | 98.3% |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Corcept Therapeutics Inc | $831m | 16.0% | 24.7% |
| Supernus Pharmaceuticals, Inc. | $865m | 26.9% | 12.3% |
| Axsome Therapeutics, Inc. | $865m | 54.2% | 57.0% |
| Pacira Biosciences, Inc. | $746m | 5.7% | 3.7% |
| Amphastar Pharmaceuticals, Inc. | $730m | 1.0% | 10.5% |
| Harmony Biosciences Holdings, Inc. | $960m | 24.3% | 24.4% |
Compare with peers
- Supernus Pharmaceuticals, Inc. revenue
- Axsome Therapeutics, Inc. revenue
- Pacira Biosciences, Inc. revenue
- Amphastar Pharmaceuticals, Inc. revenue
- Harmony Biosciences Holdings, Inc. revenue
Head to head: CORT vs SUPNAXSM vs CORTCORT vs PCRX
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies